Drug Discovery World
OCTOBER 4, 2022
Using its proprietary compound screening platform, Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau self-association that are easy to administer and cost-effective. . With its recent award of $3.35
Drug Discovery World
JANUARY 26, 2023
molecule/compound screening), real-time (or even faster) medical simulations (imagine “in silico” clinical trials with virtual humans) and super-fast whole genome sequencing and analytics. Quantum simulations also present numerous medical applications, from fast drug design (e.g.
Drug Discovery World
AUGUST 15, 2023
The objective of this proposal would be to identify the pro-arrhythmic side effects of potential new drugs for their earlier withdrawal from the lengthy drug discovery and development process, enabling the productivity of cardiovascular drug discovery to improve. Cardiovascular diseases are the leading cause of death globally.
Expert insights. Personalized for you.
52 
Let's personalize your content